Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 52
- Registration Number
- NCT06501625
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
- Conditions
- Interventions
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 45
- Registration Number
- NCT06478212
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Netherlands
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸University of California, San Francisco (UCSF) School of Medicine, San Francisco, California, United States
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- Conditions
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 48
- Registration Number
- NCT06465953
- Locations
- 🇯🇵
University of Fukui Hospital, Yoshida-gun, Eiheiji-cho 670-8540 Himeji, Japan
Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas
- Conditions
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 41
- Registration Number
- NCT06225999
- Locations
- 🇯🇵
National Cancer Center Hospital East (003), Kashiwa, Chiba, Japan
🇯🇵Chiba University Hospital (015), Chiba, Japan
🇯🇵Chiba Cancer Center (011), Chiba, Japan
Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in Hypertension
- Conditions
- Interventions
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 532
- Registration Number
- NCT05820880
- Locations
- 🇨🇳
Shandong Provincial Qianfoshan Hospita, Jinan, Shandong, China
🇨🇳Zaozhuang Municipal Hospital, Zaozhuang, Shandong, China
🇨🇳Tianjin People's hospital, Tianjin, Tianjin, China
A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 16
- Registration Number
- NCT05674474
- Locations
- 🇺🇸
American Research Corporation, San Antonio, Texas, United States
Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours
- Conditions
- Interventions
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 3
- Registration Number
- NCT05638334
- Locations
- 🇳🇱
UMC Gronningen Oncologie, Groningen, Netherlands
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 72
- Registration Number
- NCT05484622
- Locations
- 🇺🇸
Northwestern University (Site: 840123), Chicago, Illinois, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Florida, Cleveland, Ohio, United States
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
- Conditions
- Interventions
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Registration Number
- NCT05312372
Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 7
- Registration Number
- NCT05223673
- Locations
- 🇯🇵
National Cancer Center Hospital East, Chiba, Japan
🇺🇸University of Michigan Oncology Clinic | Rogel Cancer Center, Ann Arbor, Michigan, United States
🇧🇪UZA Edegem, Edegem, Belgium